Rufinamide

證據等級: L5

預測適應症: 5 個

One-Sentence Summary

Rufinamide is a triazole-derivative anticonvulsant; within this evidence pack, its established role is referenced only indirectly as basis therapy for Lennox-Gastaut syndrome (the formal original_indications field is empty). The TxGNN model predicts it may be effective for febrile infection-related epilepsy syndrome (FIRES), but this is currently supported by 0 clinical trials and 0 publications — the prediction score alone.

Quick Overview

Item	Content
Original Indication	Not confirmed in evidence pack (`original_indications` is empty); Lennox-Gastaut syndrome is referenced only within the rank-5 rationale text, pending TFDA label confirmation (DG001)
Predicted New Indication	Febrile infection-related epilepsy syndrome (FIRES)
TxGNN Prediction Score	99.57%
Evidence Level	L5 (model prediction only — no clinical trials or literature identified)
Norway Market Status	未上市 (Not Marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action (MOA) data for rufinamide is not available in this evidence pack — this is flagged as a High-severity data gap (DG002). Within the pack's own text, rufinamide's use in Lennox-Gastaut syndrome (LGS) — a severe childhood epileptic encephalopathy frequently involving epileptic spasms and multiple seizure types — is cited as existing "indication basis" (see rank-5 rationale), and the drug's presumed broad-spectrum sodium-channel modulation is used elsewhere in the pack to argue plausibility for related syndromes.

For the top-ranked candidate, febrile infection-related epilepsy syndrome (FIRES), the pack does not yet contain a specific mechanistic rationale (mechanistic_link/similarity_to_original are marked "pending"). FIRES is a rare, severe epileptic encephalopathy triggered by febrile illness that frequently progresses to super-refractory status epilepticus and is often treated with agents effective in other refractory epileptic encephalopathies. Given rufinamide's referenced role in LGS and the sodium-channel mechanism invoked for adjacent candidates in this same pack, extension to FIRES is mechanistically plausible in principle — but currently this rests solely on the TxGNN score, with no confirmatory trial, ICTRP, or literature evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Norway Market Information

Rufinamide is not currently marketed and has zero authorizations on file (total_licenses: 0, licenses: []) — no marketing-authorization table can be generated from this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Data gap note: TFDA/product-label warnings and contraindications are marked as a Blocking data gap (DG001) — per the evidence pack, this specifically prevents entry into the S1 safety initial-assessment stage. No key warnings, contraindications, or DDI records are currently on file (ddi.query_status: not_found).

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked indication (FIRES) has Evidence Level L5 — a TxGNN score with zero supporting trials or literature — and the drug is unmarketed with a blocking data gap on safety labeling (DG001), which by itself prevents any S1 safety assessment.

To proceed, the following is needed:

TFDA product label (warnings/contraindications) — resolves DG001, currently blocking
Confirmed mechanism of action via DrugBank API — resolves DG002
Confirmation of rufinamide's actual original approved indication(s), since original_indications is currently empty
Targeted literature/clinical-trial search specific to FIRES to move beyond L5
Regulatory pathway assessment, given zero current market authorizations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.